2:54 PM
Apr 16, 2018
 |  BC Extra  |  Preclinical News

Anti-GD2 CAR T could treat midline gliomas

A study published in Nature Medicine suggests that CAR T cells targeting ganglioside GD2 could help treat diffuse midline gliomas with mutated histone H3 K27M.

GD2 has been identified as a target to treat cancers such as neuroblastoma. However, treatment options are limited for diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas with the H3 K27M mutation -- aggressive and fatal pediatric brain cancers.

Scientists from Stanford University School of Medicine identified high GD2 expression in cell...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >